{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-047322","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.620626+00:00","generated_at":"2026-05-17T01:24:13.831691+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B","bullets":["Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).","Selective CBP degrader CBPd-171 advancing to non-GLP toxicology studies in Q4 2025; IND-ready in 2026 for EP300-mutant cancers and ER+ breast cancer.","Selective EP300 degrader demonstrates efficacy in >70% of hematological malignancies and IMiD-resistant multiple myeloma without thrombocytopenia.","All three programs leverage novel degrader technology to overcome historical challenges of high homology with ARID1A, CBP/EP300.","Company hosting virtual investor event on October 30, 2025 at 12 p.m. ET to present data."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-047322","json":"https://secwatch.observer/filing/0001628280-25-047322.json","markdown":"https://secwatch.observer/filing/0001628280-25-047322.md","text":"https://secwatch.observer/filing/0001628280-25-047322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025047322/0001628280-25-047322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025047322/fhtx-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:24:13.831691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}